Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiomed sales weighed on the unit’s performance.
Source: FierceBiotech
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.